Suzhou Fushilai Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 259.13 million compared to CNY 252.14 million a year ago. Revenue was CNY 272.36 million compared to CNY 257.47 million a year ago.

Net income was CNY 90 million compared to CNY 62.98 million a year ago. Basic earnings per share from continuing operations was CNY 1.1221 compared to CNY 0.9161 a year ago. Diluted earnings per share from continuing operations was CNY 1.1221 compared to CNY 0.9161 a year ago.